Limited benefit seen in patients with established cirrhosis, however
More noteworthy research from the EASD 2024 meeting
Saxenda group six times more likely to lose at least 5% of BMI
News and commentary from the endocrinology world
Approximately one-fourth of new users in 2023 did not have type 2 diabetes